SkyePharma has received a milestone payment of $10 million from Pacira Pharmaceuticals, following the launch of Exparel in the U.S. Exparel’s NDA was approved by the FDA on October 31, 2011.   Under the terms of the sale of SkyePharma’s former injectable business, now called Pacira Pharmaceuticals, Inc, SkyePharma is also entitled to receive further contingent milestone payments of as much as $52 million, as well as 3% of net sales of Exparel in the U.S., Japan, UK, France, Germany, Italy ...